Maxim Group slashes price target on Kazia Therapeutics Limited ADR [KZIA] – find out why.
Kazia Therapeutics Limited ADR [NASDAQ: KZIA] closed the trading session at $0.31. The company report on March 21, 2024 at 8:52 AM that Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases. Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology